Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients

American Journal of Psychiatry

Volumn 166, Issue 11, 2009, Pages 1251-1257

  Compton, Michael T ^a   Kelley, Mary E ^a   Ramsay, Claire E ^a   Pringle, Makenya ^a   Goulding, Sandra M ^a   Esterberg, Michelle L ^a   Stewart, Tarianna ^a   Walker, Elaine F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS;

ADULT; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CLINICAL ASSESSMENT; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; GENDER; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HOSPITAL; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RETROSPECTIVE STUDY; RISK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SUBSTANCE ABUSE; SURVIVAL RATE; SYMPTOM; TOBACCO DEPENDENCE;

ADULT; AGE OF ONSET; ALCOHOLISM; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 70449371879     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.09030311     Document Type: Article

References (57)

1. Linszen DH, Dingemans PM, Lenior ME: Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51:273-279
2. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P: Cannabis and schizophrenia: impact on onset, course, psychopathology, and outcomes. Eur Arch Psychiatry Clin Neurosci 2002; 252:86-92 (Pubitemid 36056682)
3. Green B, Young R, Kavanagh D: Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005; 187:306-313
4. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE: Prevalence and severity of substance use disorder and onset of psychosis in first-admission psychotic patients. Psychol Med 1998; 28:1411-1419 (Pubitemid 28521606)
5. Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, Harrison G: Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999; 174:150-153 (Pubitemid 29089289)
6. Hambrecht M, Häfner H: Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Austr N Z J Psychiatry 2000; 34:468-475
7. Addington J, Addington D: Impact of an early psychosis program on substance use. Psychiatr Rehab J 2001; 25:60-68
8. Compton MT, Furman AC, Kaslow NJ: Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res 2004; 71:61-64
9. Barnes TRE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM: Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006; 188:237-242
10. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD: Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr Res 2006; 81:145-150 (Pubitemid 43107688)
11. Stewart T, Goulding SM, Esterberg ML, Pringle M, Compton MT: A descriptive study of nicotine, alcohol, and cannabis use in urban, socially-disadvantaged, predominantly African American patients with first-episode nonaffective psychosis. Clinical Schizophrenia and Related Psychoses (in press)
12. Van Mastrigt S, Addington J, Addington D: Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol 2004; 39:69-72
13. Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD: Patterns and predictors of substance use and daily tobacco use in first-episode psychosis. Austr N Z J Psychiatry 2005; 39:892-898 (Pubitemid 43904454)
14. Addington J, Addington D: Patterns, predictors, and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007; 115:304-309 (Pubitemid 46425747)
15. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, Pernet DE, Kirkbride JB, Murray GK, Bullmore ET, Jones PB: Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 2007; 190:515-520
16. Harrison I, Joyce EM, Mutsatsa SH, Hutton SB, Huddy V, Kapasi M, Barnes TR: Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med 2008; 38:79-88
17. Silver H, Abboud E: Drug abuse in schizophrenia: comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophr Res 1994; 13:57-63 (Pubitemid 24227897)
18. Bühler B, Hambrecht M, Löffler W, an der Heiden W, Häfner H: Precipitation and determination of the onset and course of schizophrenia by substance abuse: a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54:243-251
19. Mauri M, Volonteri L, De Gaspari I, Colasanti A, Brambilla M, Cerruti L: Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health 2006; 2:1-8 (Pubitemid 43676900)
20. Allebeck P, Adamsson C, Engstrom A, Rydberg U: Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand 1993; 88:21-24
21. Hambrecht M, Häfner H: Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996; 40:1155-1163
22. Veen ND, Selten J-P, van der Tweel I, Feller WG, Hoek HW, Kahn RS: Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004; 161:501-506 (Pubitemid 38326105)
23. González-Pinto A, Vega P, Ibáñez B, Mosquera F, Barbeito S, Gutiérrez M, Ruiz de Azúa S, Ruiz I, Vieta E: Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry 2008; 69:1210-1216
24. King M, Coker E, Leavey G, Hoare A, Johnson-Sabine E: Incidence of psychotic illness in London: comparison of ethnic groups. Br Med J 1994; 309:1115-1119 (Pubitemid 24324851)
25. Van Os J, Castle DJ, Takei N, Der G, Murray RM: Psychotic illness in ethnic minorities: clarification from the 1991 census. Psychol Med 1996; 26:205-210
26. Sharpley MS, Hutchinson G, Murray RM, KcKenzie K: Understanding the excess of psychosis among the African-Caribbean population in England: review of current hypotheses. Br J Psychiatry 2001; 78:s60-s68
27. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS: Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004; 291:2114-2121
28. Cockrell JR, Folstein MF: Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988; 24:689-692
29. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1998
30. Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA: Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res 2000; 44:1-10 (Pubitemid 30365202)
31. Norman RMG, Malla AK: Course of Onset and Relapse Schedule: Interview and Coding Instruction Guide. London, Ontario, London Health Sciences Centre, Prevention and Early Intervention for Psychosis Program, 2002
32. Compton MT, Carter T, Bergner E, Franz L, Stewart T, Trotman H, McGlashan TH, McGorry PD: Defining, operationalizing, and measuring the duration of untreated psychosis (DUP): advances, limitations, and future directions. Early Interv Psychiatry 2007; 1:236-250
33. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-276 (Pubitemid 18039085)
34. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994; 81:515-526
35. Yung AR, McGorry PD: The initial prodrome in psychosis: descriptive and qualitative aspects. Austr N Z J Psychiatry 1996; 30:587-599
36. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28-37
37. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34:605-613
38. Iversen L: Cannabis and the brain. Brain 2003; 126:1252-1270
39. Ashton CH: Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178:101-106 (Pubitemid 32158071)
40. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D: Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001; 103:9-15
41. Sundram S, Dean B, Copolov D: The endogenous cannabinoid system in schizophrenia, in Marijuana and Madness: Psychiatry and Neurobiology. Edited by Castle DJ, Murray R. Cambridge, England, Cambridge University Press, 2004, pp 127-141
42. Zavitsanou K, Garrick T, Huang XF: Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress Neuropsychopharmacol Biol Psychiatry 2004; 28:355-360
43. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D: Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10:1665-1669
44. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V: Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids Health Dis 2003; 2:5-14 (Pubitemid 38813920)
45. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkötter J, Piomelli D: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacol 2004; 29:2108-2114 (Pubitemid 39486563)
46. Castle DJ, Solowij N: Acute and subacute psychomimetic effects of cannabis in humans, in Marijuana and Madness: Psychiatry and Neurobiology. Edited by Castle D, Murray R. Cambridge, England, Cambridge University Press, 2004, pp 41-53
47. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH: Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57:594-608 (Pubitemid 40409699)
48. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370:319-328 (Pubitemid 47094993)
49. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325:1212-1213 (Pubitemid 35398785)
50. Gorwood P, Leboyer M, Jay M, Payan C, Feingold J: Gender and age at onset in schizophrenia: impact of family history. Am J Psychiatry 1995; 152:208-212
51. Ripoll N, Bronnec M, Bourin M: Nicotinic receptors and schizophrenia. Curr Med Res Opin 2004; 20:1057-1074
52. Mobascher A, Winterer G: The molecular and cellular neurobiology of nicotine abuse in schizophrenia. Pharmacopsychiatry 2008; 41(suppl 1):S51-S59
53. O'Farrell TH, Maisto, SA: The utility of self report and biological measures of drinking in alcoholism treatment outcome studies. Adv Behav Res Ther 1987; 9:91-125
54. Brown J, Kranzler HR, Del Boca FK: Self-reports by alcohol and drug abuse inpatients: factors affecting reliability and validity. Br J Addict 1992; 87:1013-1024
55. Jeste DV, McAdams LA, Palmer BW, Braff D, Jernigan TL, Paulsen JS, Stout JC, Symonds LL, Bailey A, Heaton RK: Relationship of neuropsychological and MRI measures to age at onset of schizophrenia. Acta Psychiatr Scand 1998; 98:156-164
56. Tuulio-Henriksson A, Partonen T, Suvisaari J, Haukka J, Lonnqvist J: Age at onset and cognitive functioning in schizophrenia. Br J Psychiatry 2004; 185:215-219 (Pubitemid 39208222)
57. Smit F, Boiler L, Cuijpers P: Cannabis use and the risk of later schizophrenia: a review. Addiction 2004; 99:425-430 (Pubitemid 38496658)